Clinical Trial Update: SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating SHR-A1811 in combination with Adebrelimab for HER2-low expressing metastatic breast cancer, and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Adebrelimab (adebrelimab)
• SHR-A1811

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Breast Cancer | Phase 2 | Status: RECRUITING